Focus
MSCI
Vanguard Funds Invest in Chinese Military Companies, Report Says
Congressional scrutiny over Wall Street’s role in financing Chinese military companies has been on the rise.
We’re ‘Subsidizing Our Own Destruction’: Rep. Mike Gallagher on Wall Street’s Investments Into Blacklisted Chinese Companies
“MSCI and BlackRock have directed investment in companies that produce the Chinese Communist Party’s military aircraft, its aircraft carriers, its aerospace technology, its artillery shells, even advanced nuclear technology,” says Rep. Mike Gallagher.
BlackRock, MSCI Draw Congressional Scrutiny for China Investments
The world’s largest asset manager and leading index provider are facing congressional probes for facilitating American dollars into Chinese companies that the United States has deemed to be fueling Chinese military growth or human rights abuses.
A $4 Billion Error, and Cold Facts About Investing in China
One of China’s biggest drugmakers said it overstated its assets by $4.4 billion, calling into question the quality and standard of accounting at Chinese listed companies.
Vanguard Funds Invest in Chinese Military Companies, Report Says
Congressional scrutiny over Wall Street’s role in financing Chinese military companies has been on the rise.
We’re ‘Subsidizing Our Own Destruction’: Rep. Mike Gallagher on Wall Street’s Investments Into Blacklisted Chinese Companies
“MSCI and BlackRock have directed investment in companies that produce the Chinese Communist Party’s military aircraft, its aircraft carriers, its aerospace technology, its artillery shells, even advanced nuclear technology,” says Rep. Mike Gallagher.
BlackRock, MSCI Draw Congressional Scrutiny for China Investments
The world’s largest asset manager and leading index provider are facing congressional probes for facilitating American dollars into Chinese companies that the United States has deemed to be fueling Chinese military growth or human rights abuses.
A $4 Billion Error, and Cold Facts About Investing in China
One of China’s biggest drugmakers said it overstated its assets by $4.4 billion, calling into question the quality and standard of accounting at Chinese listed companies.